




Review: The Efficacy of Cannabidiol (CBD) as 




Psychotic disorders such as schizophrenia are widespread and severely disabling; 
however, current pharmacological treatments are unsatisfactory due to major 
side effects.  The current review discusses the therapeutic potential of cannabidiol 
(CBD), a non-psychoactive component of cannabis, as an antipsychotic drug. 
Research lines including studies based on animal models of psychosis, human 
experimental studies, neuroimaging studies, epidemiological studies, and clinical 
studies are reviewed. The studies described provide empirical support for the 
antipsychotic effects of CBD and indicate reduced side effects, high tolerability, 
and superior cost-effectiveness compared to regular antipsychotic medication. It 
is concluded that CBD may prove a safe and attractive alternative treatment for 
psychotic conditions. However, current evidence largely stems from 
experimental, non-clinical studies. Large-scale randomized clinical trials are 
needed before this can be implemented in practice. 
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INTRODUCTION 
Schizophrenia is a chronic, debilitating mental disorder that affects 0.7 percent of the world’s 
population (Tandon, Nasrallah, & Keshavan, 2008). It is characterized by a highly heterogeneous 
clinical manifestation of positive (e.g., delusions, hallucinations), negative (e.g., apathy, blunted 
affect), cognitive (e.g., impaired executive function, working memory), disorganization (e.g., 
formal thought disorder), psychomotor (e.g., catatonia) and mood (e.g., increased arousal, 
depression) symptoms, whereby official diagnosis requires the presence of at least two major 
symptoms for a minimum period of one month (American Psychiatric Association, 2013). Onset 
of psychotic symptoms is usually in adolescence or early adulthood, and genetic factors 
contribute over 80% of the liability for developing schizophrenia (Tandon et al., 2008). It tends 
to be a chronic and relapsing condition with generally incomplete remissions, and is associated 
with shortened lifespan and significant impairments in social and vocational functioning (e.g., 
reduced employment rates, increased incarceration and homelessness rates; Rössler, Salize, van 
Os, Riecher-Rössler, 2005). 
The cornerstone of treatment for schizophrenia is pharmacological therapy, and the 
common mechanism of most antipsychotic drugs is the blockage of dopamine D2 receptors 
(Gardner, Balsdessarini, & Waraich, 2005). However, current antipsychotic medication is only 
partially effective – it improves positive symptoms but is less effective for negative symptoms – 
and is associated with frequent serious side effects (Tandon, Nasrallah, & Keshavan, 2010). 
Typical antipsychotic drugs (first-generation antipsychotics) commonly induce extrapyramidal 
side effects (Parkinson-like motor disturbances), stemming from dopamine depletion of the 
nigrostriatal pathway due to continued consumption of the medication (Stahl, 2001). Atypical 
antipsychotics (second-generation antipsychotics) may lead to fewer extrapyramidal side effects, 
but carry other adverse consequences such as increased risk for cardiovascular disease, sexual 
dysfunction, and significant weight gain. A large proportion of patients fail to adhere to 
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pharmacological antipsychotic treatment due to such tolerability issues (Leucht, Heres, Kissling, 
& Davis, 2011). Consequently, there is a persistent need for new treatment options against 
schizophrenia that are both safe and effective. 
 However, this search is impeded by the complex pathogenesis of the disorder, 
which is known to involve multiple brain neurotransmitter systems (Rogers & Goldsmith, 2009). 
Besides the dopaminergic, serotonergic, and glutamatergic systems, recent findings indicate 
that the human endogenous cannabinoid system is significantly involved in the development of 
schizophrenia. Specifically, administration of 9-tetrahydrocannabinol (THC), which is the 
main psychoactive compound of cannabis, can acutely induce transient psychotic-like 
symptoms in healthy volunteers, and exacerbate psychotic symptoms in schizophrenic patients 
(D’Souza et al., 2005). Moreover, the use of cannabis has been reported to increase the risk for 
developing a psychotic disorder (e.g., Moore et al., 2007), although methodological issues across 
studies raise obstacles to definite statements of a causal relationship (McLaren, Silins, 
Hutchinson, Mattick, & Hall, 2010). On the other hand, cannabis has been implicated in 
medicinal use since prehistoric times (e.g., against inflammatory conditions and asthma; 
Schubart et al., 2014), and it may in fact carry both a risk and a remedy for psychotic conditions 
in itself: Cannabidiol (CBD) is a non-psychoactive component of cannabis, and the natural 
counterpart of THC (Mechoulam, Peters, Murillo-Rodriguez, & Hanus, 2007). The concentration 
of these two major cannabinoids in cannabis appears to follow an inverse relationship. In 1974, 
it was reported that CBD could counteract the psychotomimetic and anxiety- inducing effects 
of THC (Karniol et al., 1974), providing a first indication of its antipsychotic and anxiolytic 
properties. Interest in CBD’s medicinal benefits has been growing since, and evidence is 
accumulating for its potential as an antipsychotic agent. The current review aims to provide an 
overview and an evaluation of the evidence-base of CBD as an antipsychotic agent. 
The pharmacological mechanism through which cannabidiol exerts its antipsychotic 
effects is currently not fully understood, but there is evidence for multiple mechanisms of action. 
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Despite its low affinity for CB1 and CB2 receptors, CBD is capable of antagonizing CB1/CB2 
receptor agonists (such as THC and the two main endocannabinoids 2-arachidonoylglycerol and 
anandamide) at relatively low concentrations (Pertwee, 2008). Other mechanisms of action 
include antagonism of the recently discovered GPR55 receptor; transient receptor potential 
vanilloid type 1 (TRPV1) agonism; transient receptor potential vanilloid type 2 (TRPV2) agonism; 
modest affinity agonism of the 5-HT1A serotonin receptor; antagonism of the putative abnormal-
CBD receptor; and regulation of intracellular [Ca2+] (Izzo, Borrelli, Capasso, Di Marzo, & 
Mechoulam, 2009; Russo, Burnett, Hall, & Parker, 2005). Moreover, there is evidence that CBD 
blocks the degradation of anandamide (AEA) by inhibiting the fatty acide amine hydrolase 
(FAAH) enzyme, which is the main metabolite of AEA, thereby enhancing AEA levels in the 
brain (Bisogno et al., 2001). Leweke and colleagues (2012) found that an increase in AEA levels 
was associated with a decrease in psychotic symptoms in patients treated with CBD. Moreover, 
cerebrospinal anandamide levels were found to be significantly higher in schizophrenia patients 
relative to healthy subjects, but they correlated negatively with psychotic symptoms (Giuffrida 
et al., 2004). Therefore, it was proposed that anandamide release might serve as an adaptive 
compensatory mechanism during acute psychoses, representing a negative feedback response 
to overactivation of dopamine D2 receptors (Leweke et al., 2007). 
Evaluating the evidence for the efficacy of cannabidiol (CBD) as potential 
antipsychotic medication 
Several lines of evidence suggest that CBD has potential as an antipsychotic treatment. These 
include studies based on animal models of psychosis, human experimental studies, 
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Animal studies 
Animal models employing behavioral as well as neurochemical methodology suggest that CBD 
has a pharmacological profile similar to that of an atypical antipsychotic drug (Zuardi, Crippa, 
Hallak, Moreira, & Guimarães, 2006). Across several studies, CBD demonstrated the same 
effectiveness in reducing psychotic-like symptoms in rodents, compared to a typical 
antipsychotic (haloperidol) and an atypical antipsychotic (clozapine; Moreira & Guimarães, 
2005; Zuardi, Rodrigues, & Cunha, 1991; Gururajan, Taylor, & Malone, 2011). These effects were 
shown both within dopamine- and glutamate-based models, where CBD resembled atypical 
antipsychotic agents in that no extrapyramidal side effects were induced. CBD also proved 
capable of reversing THC-induced effects such as reduced social interaction (Malone, Jongejan, 
& Taylor, 2009) and apomorphine-induced sniffing, biting and stereotyped behavior in rats 
(Zuardi et al., 1991). Furthermore, in neurochemical studies CBD revealed similar neural 
activation patterns compared to atypical antipsychotics (Guimarães, Zuardi, Del Bel, & 
Guimarães, 2004). Taken together, preclinical data provide for support CBD’s antipsychotic 
potential, suggesting a profile similar to that of atypical antipsychotic drugs. 
 
Human experimental studies 
Across multiple experimental models of psychosis, studies with healthy volunteers indicated 
antipsychotic-like properties of CBD. Research paradigms including binocular depth inversion 
and a mismatch negativity model suggested positive effects of CBD in attenuating psychotic-like 
symptoms and increasing cognitive performance (Leweke, Schneider, Radwan, Schmidt, & 
Emrich, 2000; Juckel, Roser, Nadulski, Stadelmann, & Gallinat, 2007). In addition, CBD 
attenuated psychotic-like effects in a glutamate-based model (Bosi, Hallak, Dursun, Deakin, & 
Zuardi, 2003). Finally, studies comparing the psychotomimetic effects of THC and CBD in 
humans revealed that CBD pretreatment (before THC admission) blocked the emergence of 
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psychotic symptoms, and posttreatment reduced THC induced effects, particularly anxiety 
(Bhattacharyya et al., 2010; Zuardi, Shirakawa, Finkelfarb, & Karniol, 1982; Crippa, Zuardi, 
Martin-Santos, & Bhattacharyya, 2009). 
 
Neuroimaging studies 
Imaging studies also provide several clues of a potential antipsychotic effect of CBD. A series of 
functional imaging studies by Bhattacharyya and colleagues investigated brain activation 
patterns under THC and CBD in 15 healthy volunteers during tasks often impaired in psychosis 
(Bhattacharyya et al., 2009, 2010, 2012; Borgwardt et al., 2008; Fusar-Poli et al., 2009; Winton-
Brown et al., 2011). THC and CBD were shown to have opposing effects on regional brain 
activation in areas associated with the pathophysiology of psychotic disorders, including the 
striatum, the prefrontal cortex and the medial temporal cortex. In a structural imaging study, 
Demirakca et al. (2011) found that CBD had a protective effect on cannabis use-associated gray 
matter volume reduction in the hippocampus. Hippocampal volume loss is a frequent finding in 
schizophrenia patients (Walker, Mittal, & Tessner, 2008); thus, a potential neuroprotective 
effect is a desirable feature of antipsychotic medication. 
 
Epidemiological studies 
Several epidemiological studies detected a relationship between psychosis or psychotic 
symptoms and THC/CBD concentration. Comparing cannabis use habits of first episode 
psychosis patients and healthy cannabis users revealed that patients were significantly more 
likely to have used high-potency cannabis, containing high THC and low CBD concentrations, 
for a longer duration and with higher frequency (Di Forti et al., 2009). Moreover, Morgan and 
colleagues showed that cannabis users who had a higher content of CBD in hair samples 
exhibited lower levels of positive symptoms such as delusions and hallucinations, suggesting 
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that the presence of CBD in the strain of cannabis consumed has a protective function against 
psychotic symptoms induced by THC (Morgan & Curran, 2008; Morgan et al., 2012). This finding 
was further replicated by Schubart et al. (2011). Hence, there are consistent findings that 




Safety and side effect studies of CBD were required before human administration (for a recent 
review see Bergamaschi, Queiroz, Zuardi, & Crippa, 2011). Extensive reports of CBD 
administration across a wide range of concentrations did not detect severe side effects or toxic 
effects in animal studies. In human studies, CBD did not induce side effects across a wide range 
of dosages including acute and chronic dose regimens, and it was shown that chronic CBD use 
with high doses up 1500 mg/kg a day were well tolerated. However, in vitro and in vivo studies 
showed potential drug metabolism interactions, cytotoxicity, and decreased receptor activity. 
The available data suggest that CBD can be safely administered over a wide dose range, but 
further double-blind, placebo-controlled trials are still needed to assess the effects of 
cannabidiol on biological systems. 
 
Clinical studies 
Clinical studies also attest to the antipsychotic efficacy of CBD. Zuardi and colleagues published 
several case studies and pilot studies demonstrating significant improvement of psychotic 
symptoms with CBD monotherapy in patients with psychotic symptoms (Zuardi et al., 1995, 
2006, 2009, 2010). No adverse effects on motor functioning or cognition were detected. However, 
there were no, or only small improvements in treatment-refractory schizophrenia patients. To 
date, five randomized controlled trials (RCTs) and one open-label study investigating the acute 
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antipsychotic and potential procognitive effects of cannabidiol have been initiated, two of which 
have published data (see Leweke, Mueller, Lange, & Rohleder, 2016). The first double-blind, 
randomized controlled clinical trial compared treatment with CBD versus the atypical 
antipsychotic amisulpride in patients with acute paranoid schizophrenia or schizophreniform 
disorder (n=42) over a 4-week trial (Leweke et al., 2012). CBD and amisulpride displayed equal 
therapeutic efficacy in reducing psychotic symptoms; however, CBD treatment was 
accompanied by significantly fewer side effects (no prolactin increase, weight gain, or 
extrapyramidal symptoms). The same research group conducted a RCT in a double-blind cross-
over design, comparing CBD versus placebo in 29 first-episode schizophrenic patients within a 
4-week trial (University of Cologne, 2008). Results are currently pending publication. 
A third RCT by Ranganathan et al. (Yale University, 2009) compared CBD and placebo 
over six weeks as an addition to a stable risperidone treatment (n=36), focusing on improvement 
of cognitive functioning. Results are yet to be published. A fourth double-blind RCT has recently 
been completed comparing effects of CBD versus placebo in adjunction with antipsychotic 
medication in 88 patients with psychotic disorders (GW Research Ltd, 2013). While results have 
not been formally published yet, it was recently announced that CBD was consistently superior 
to placebo regarding psychopathology and showed a reassuring safety profile (GW 
Pharmaceuticals, 2015).  Two more clinical trials are currently ongoing: a study by Leweke and 
colleagues, comparing CBD to olanzapine and a placebo (Central Institute of Mental Health, 
2015), and an open-label, add-on trial investigating of CBD in patients with treatment-refractory 
psychotic disorders (King’s College London, 2013). In sum, currently available data suggest that 
CBD may exert clinically relevant antipsychotic effects while displaying a superior side-effect 
profile compared to conventional medication. However, preliminary evidence is limited with no 










In conclusion, the preclinical and clinical studies discussed in this review provide promising 
initial support for CBD as an effective and safe antipsychotic compound. Preliminary evidence 
points to high tolerability, superior cost-effectiveness and a promising side effect profile, 
suggesting an attractive alternative to current antipsychotic treatment. However, the vast 
majority of current evidence stems from experimental non-clinical studies, with only limited 
clinical data available. Some clinical trials are currently ongoing and some studies remain to be 
published, but the duration of treatment is limited to six weeks of treatment at maximum and 
sample sizes are not sufficient to warrant conclusions. As suggested by Leweke et al. (2o16), 
large-scale, randomized clinical trials both in the acute treatment as well as in the maintenance 
phase, for six months or longer are required to prove the safety and efficacy of cannabidiol in 
schizophrenia. Further, should this novel treatment option be introduced into clinical practice, 
careful monitoring of CBD use in humans is warranted, given the above-mentioned side effects 
that were found in some studies. 
 Interest in the endocannabinoid system has immensely increased over the years, as it 
may play a role in several disorders, including a variety of psychiatric conditions (for a recent 
review see Lutz, Marsicano, Maldonado, & Hillard, 2015). The last decade has shown a notable 
increase in scientific literature on CBD, owing to the identification of its anti-inflammatory and 
neuroprotective effects. Not only has it evolved as a new target for treatment approaches to 
schizophrenia, but other potential therapeutic applications of CBD may include anxiety and 
mood disorders (Crippa, Zuardi, & Hallak, 2010), as well as epilepsy (Dravet’s syndrome) and 
other neurological disorders (Project CBD, 2015). Given the significant favorable evidence 
pointing to the therapeutic potential of cannabidiol in psychotic and other conditions, 
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